Copyright
©The Author(s) 2023.
World J Gastroenterol. Jan 7, 2023; 29(1): 144-156
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.144
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.144
Ref. | Nationality | Number of patients | Etiology of cirrhosis | MHE diagnosis | Sample | Method | Microbiota alteration |
Zhang et al[8] | China | 51 | AIH, HBV, PBC, alcohol | NCT-A DST | Stool | 16S rRNA pyrosequencing | Enriched Streptococcus salivarius |
Wang et al[14] | China | 98 | HBV, HCV, others | NCT-A DST | Stool | 16S rRNA sequencing | Enriched Proteobacteria, especially Pasteurellaceae Haemophilus and Alcaligenaceae Parasutterella |
Luo et al[29] | China | 143 | HBV | PHES | Stool | 16S rRNA sequencing | Enriched Streptococcus salivarius and Veillonella |
Liu et al[76] | China | 55 | HBV, HCV, alcohol, others | NCT-A BAEP | Stool | Stool bacterial culture | Overgrowth of E. coli and Staphylococcus spp. |
Bajaj et al[27] | United States | 97 | HCV, alcohol, NASH, others | ICT PHES | Stool | Shotgun metagenomic sequencing | Alistipes ihumii, Prevotella copri, and Eubacterium spp. were higher, while Enterococcus spp. were uniquely lower in MHE diagnosed by ICT |
Bajaj et al[28] | United States | 247 | HCV, alcohol, NASH, others | PHES ICT Stroop | Stool | Multi-tagged sequencing | Enriched Lactobacillaceae |
Ref. | Design | Patients | Duration | Sample | Method | Microbiota alteration | Therapeutic effect |
Lactulose | |||||||
Wang et al[14] | Multi-centre, open-label, randomized controlled trial | lactulose (n = 67), control (n = 31) | 60 d | Stool | 16S rRNA sequencing | Higher abundances of Bacteroidetes, Firmicutes, Actinobacteria, and Proteobacteria were in non-responders for lactulose | Significantly ameliorated MHE |
Rifaximin | |||||||
Bajaj et al[56] | Controlled clinical trial | MHE patients before/after rifaximin (n = 20) | 8 wk | Stool | Multi-tagged pyrosequencing, GC/LC-MS | Modest decrease in Veillonellaceae and increase in Eubacteriaceae, with significant changes in metabolite correlations | Significant improvement in endotoxemia and cognition |
Probiotics | |||||||
Lactobacillus GG | |||||||
Bajaj et al[74] | Randomized phase I, placebo-controlled trial | Probiotic (n = 14), placebo (n = 16) | 8 wk | Stool | Multi-tagged pyrosequencing, GC/LC-MS | Decreased Enterobacteriaceae and increased Lachnospiraceae and Clostridiales Incertae Sedis XIV, with significant alterations in metabolite correlations with amino acid and secondary bile acid metabolism | Attenuated endotoxemia and decreased TNF-α without change in cognition |
Probiotics | |||||||
Clostridium butyricum combined with Bifidobacterium infantis | |||||||
Xia et al[73] | Randomized controlled trial | Probiotic (n = 30), placebo (n = 37) | 3 mo | Stool | 16S rRNA sequencing | Increased Clostridium cluster I and Bifidobacterium, decreased Enterobacteriaceae and Enterococcus | Reduced ammonia and improved cognition |
Escherichia coli Nissle 1917 strain | |||||||
Manzhalii et al[75] | Single-centre, open-label, randomized trial | Probiotic (n = 15), lactulose (n = 15), rifaximin (n = 15) | 1 mo | Stool | 16S rRNA sequencing | Normalized Bifidobacterium and Lactobacilli abundance | Reduced ammonia and pro-inflammatory cytokines and improved cognition |
Rifaximin plus probiotic | |||||||
Zuo et al[84] | Controlled clinical trial | Rifaximin (n = 7), rifaximin plus probiotic (n = 7) | 4 wk | Stool | 16S rRNA sequencing | Both treatments alone reduced the overall microbiome diversity, with decreased Streptococcus and Faecalibacterium, Clostridium and increased Lactobacillus | Rifaximin plus probiotics showed a more apparent effect |
Rifaximin plus lactulose | |||||||
Schulz et al[72] | Randomized controlled trial | Rifaximin (n = 1), rifaximin plus lactulose (n = 4) | 3 mo | Stool | 16S rRNA sequencing | Rifaximin with or without lactulose did not affect microbiota composition | MHE improvement with rifaximin lasted after the end of treatment |
Synbiotics | |||||||
Probiotics plus fermentable fiber | |||||||
Liu et al[76] | Controlled clinical trial | Synbiotic (n = 20), fermentable fiber (n = 20), placebo (n = 15) | 30 d | Stool | Stool quantitative bacteriological culture | Significant increase in non-urease-producing Lactobacillus species | Reduced ammonia and endotoxemia levels, reversal in 50% of MHE patients |
- Citation: Luo M, Xin RJ, Hu FR, Yao L, Hu SJ, Bai FH. Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy via the gut-liver-brain axis. World J Gastroenterol 2023; 29(1): 144-156
- URL: https://www.wjgnet.com/1007-9327/full/v29/i1/144.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i1.144